© The Author 2006. Published by Oxford University Press.
ARTICLE |
Impact of a Scientific Presentation on Community Treatment Patterns for Primary Breast Cancer
Affiliations of authors: Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (SHG, ZD, GNH); Sealy Center on Aging, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX (Y-FK, JF, JSG)
Correspondence to: Sharon H. Giordano, MD, MPH, Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 424, Houston, TX 77030 (e-mail: sgiordan{at}mdanderson.org).
Background: The publication of results from randomized clinical trials can have a dramatic effect on treatment patterns, but the impact of oral presentations at national scientific meetings is unknown. We investigated the temporal association between the oral presentation of the results from the Cancer and Leukemia Group B (CALGB) Study 9344 at the May 1998 meeting of the American Society of Clinical Oncology, which showed that paclitaxel improves survival of women with lymph node–positive breast cancer, and use of taxane chemotherapy for breast cancer. Methods: We studied chemotherapy use in 3341 women identified through the Surveillance, Epidemiology, and End Results–Medicare database who were diagnosed with stage I–III breast cancer in 1994–1999 at age 65 years or older and received adjuvant chemotherapy, as identified through claims data, within 1 year of diagnosis. We assessed the temporal association between the CALBG presentation and taxane use with piecewise regression analysis. Multivariable logistic regression analysis was used to determine which patient characteristics were associated with taxane use. Results: The use of taxanes increased substantially after the CALGB presentation, with absolute rates of taxane use of 5.2% before May 1998 and 23.6% in May 1998 and later. Initially, this increase was confined to patients with lymph node–positive disease (40% of whom were receiving taxanes by the end of 1999), but over time it extended to patients with lymph node–negative disease (15% of whom were receiving taxanes by the end of 1999). In multivariable analysis, patients who were treated in May 1998 or later were statistically significantly more likely to have received a taxane than patients treated before this date (estimated relative risk = 6.84, 95% confidence interval = 5.71 to 8.07). Younger patient age, larger number of lymph nodes involved, higher tumor grade, and larger tumor size were also independently associated with adjuvant taxane use. Conclusions: The oral presentation of a single study at a national conference was temporally associated with an increase in the use of taxanes for primary breast cancer, even before study publication or Food and Drug Administration approval.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- What's the Rush? The Dissemination and Adoption of Preliminary Research Results
- Steven Woloshin and Lisa M. Schwartz
J Natl Cancer Inst 2006 98: 372-373.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  L. B. Marks, J. Zeng, and L. R. Prosnitz One to Three Versus Four or More Positive Nodes and Postmastectomy Radiotherapy: Time to End the Debate J. Clin. Oncol., May 1, 2008; 26(13): 2075 - 2077. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Punglia, J. C. Weeks, B. A. Neville, and C. C. Earle Radiation Therapy After Mastectomy Between 1991 and 1999 in Elderly Women: Response to Clinical Trial Information J. Clin. Oncol., July 20, 2006; 24(21): 3474 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Woloshin and L. M. Schwartz What's the rush? The dissemination and adoption of preliminary research results. J Natl Cancer Inst, March 15, 2006; 98(6): 372 - 373. [Full Text] [PDF]
|
|